Opendata, web and dolomites

GONDOLA SIGNED

Automated Mechanical Peripheral Stimulation for motor rehabilitation in people living with Parkinson’s Disease (PD)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GONDOLA project word cloud

Explore the words cloud of the GONDOLA project. It provides you a very rough idea of what is the project "GONDOLA" about.

characterised    medications    disorder    regulates    falls    effectiveness    treatment    physical    annual    spinal    2004    stimulation    economic    automated    advancing    individuals    10m    benefits    people    ideal    gondolatm    treating    peripheral    quality    substantial    life    society    ourselves    motions    globally    stages    reducing    disabled    neurostimulation    costly    points    movements    functioning    efficacy    independence    basic    nervous    more    invasive    documented    induce    body    regard    pd    fluidity    patients    feet    causing    pattern    named    prevalence    spending    living    amps    mechanical    lessening    disease    generator    7b    slowness    mechanism    neurostimulations    delivers    therapies    parkinson    dopamine    portable    medical    neurotransmitter    cure    freezing    safety    time    walking    self    balance    risk    symptoms    2040    neurodegenerative    central    inputs    person    aligned    device    inability    gait    afferent    regulate    recommendations    hesitation    confidence    made    clinical    skills    double    cord    strategy    brain    ninds    undermine    motor    nih    families    burden    priorities   

Project "GONDOLA" data sheet

The following table provides information about the project.

Coordinator
GONDOLA MEDICAL TECHNOLOGIES SA 

Organization address
address: CORSO ELVEZIA 9 A
city: LUGANO
postcode: 6900
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.gondola-parkinson.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GONDOLA MEDICAL TECHNOLOGIES SA CH (LUGANO) coordinator 50˙000.00

Map

 Project objective

Parkinson’s disease (PD) is a neurodegenerative brain disorder, characterised by the inability of a person’s brain to produce a neurotransmitter called dopamine, lessening a person’s ability to regulate body motions. PD affects 10m people globally, its prevalence is expected to double by 2040. There is no cure for PD, current therapies focus on treating symptoms that undermine patients’ quality of life. Costs associated with PD are higher than its prevalence, causing substantial economic burden on individuals, families and society. In 2004, the annual spending in Europe on PD was €10.7b. As costly as they are, these therapies improve motor symptoms in the early stages of PD, but over time, patients have more and more reduced response to medications and become more disabled. Thus, they cannot be considered as ideal with regard to efficacy, long-term effectiveness and safety. NINDS (part of the US NIH) set recommendations addressing Gait as one of the 3 top priorities for advancing basic clinical research on PD. We have aligned ourselves with NINDS’ strategy through development of GondolaTM. GondolaTM is a portable medical device made for people living with PD. It delivers a non-invasive neurostimulation treatment named Automated Mechanical Peripheral Stimulation (AMPS). It is based on physical neurostimulations of specific points in both feet, which allow to increase the afferent inputs from the peripheral nervous system to the spinal cord, and induce a better functioning of the central pattern generator (the mechanism that regulates movements in the body). Four clinical studies have documented that AMPS is effective in improving motor skills in PD, particularly slowness of movements and freezing of gait. Users have derived the following benefits from the device: Reduced Freezing of gait, gait hesitation, slowness of movements, improved independence, self-confidence, fluidity in walking and balance, reducing the risk of falls and improving the quality of life.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GONDOLA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GONDOLA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TalentVision (2019)

INSIGHTS FOR TALENT ASSESSMENT USING COMPUTER VISION TECHNIQUES FROM NEURO PSYCHOLOGY

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More  

Manuback (2019)

MANUBACK, the smart garment for operator protection in the field of Manual Handling of Goods

Read More